Examination about the effect of the cytapheresis combination therapy for patients with inflammatory bowel disease during biologics induction and maintenance administration.

Examination about the effect of the cytapheresis combination therapy for patients with inflammatory bowel disease during biologics induction and maintenance administration. - CAPBiologics

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000024793

Enrollment

Registered

2016-11-10

Start date

2015-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Crohn&#39

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Crohn's disease made maintenance therapy with infliximab or adalimumab, the patients with ulcerative colitis. (2) The patients who used CAP combination therapy.

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
When we show the change of the anti-drug antibody with the CAP therapy, CAP therapy and anti-TNF antibody preparation combination may produce a synergistic effect.	—

Countries

Japan

Contacts

Public ContactHirotsugu Imaeda

Shiga University of Medical Science Division of Gastroenterology, Department of Medicine

imaeda@belle.shiga-med.ac.jp077-548-2217

Outcome results